Sienna Biopharmaceuticals (NASDAQ:SNNA) Stock Price Up 19.7%

Share on StockTwits

Shares of Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) rose 19.7% during mid-day trading on Wednesday . The company traded as high as $0.86 and last traded at $0.79, approximately 381,844 shares traded hands during trading. An increase of 32% from the average daily volume of 289,209 shares. The stock had previously closed at $0.66.

SNNA has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. cut shares of Sienna Biopharmaceuticals from an “overweight” rating to a “neutral” rating in a report on Monday, May 13th. ValuEngine upgraded shares of Sienna Biopharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Sienna Biopharmaceuticals presently has a consensus rating of “Buy” and an average target price of $21.67.

The company has a debt-to-equity ratio of 1.11, a current ratio of 2.43 and a quick ratio of 2.43. The company’s 50 day moving average is $0.81 and its two-hundred day moving average is $1.67. The firm has a market cap of $20.40 million, a P/E ratio of -0.22 and a beta of 2.89.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC bought a new stake in shares of Sienna Biopharmaceuticals in the second quarter valued at about $50,000. Citadel Advisors LLC lifted its stake in shares of Sienna Biopharmaceuticals by 152.3% in the second quarter. Citadel Advisors LLC now owns 40,555 shares of the company’s stock valued at $35,000 after buying an additional 24,480 shares during the period. Paloma Partners Management Co bought a new stake in shares of Sienna Biopharmaceuticals in the second quarter valued at about $60,000. Vanguard Group Inc. lifted its stake in shares of Sienna Biopharmaceuticals by 95.3% in the second quarter. Vanguard Group Inc. now owns 1,859,306 shares of the company’s stock valued at $1,617,000 after buying an additional 907,318 shares during the period. Finally, A.R.T. Advisors LLC lifted its stake in shares of Sienna Biopharmaceuticals by 84.5% in the second quarter. A.R.T. Advisors LLC now owns 32,653 shares of the company’s stock valued at $28,000 after buying an additional 14,954 shares during the period. Institutional investors and hedge funds own 49.30% of the company’s stock.

Sienna Biopharmaceuticals Company Profile (NASDAQ:SNNA)

Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.

Read More: Neutral Rating

Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

First Internet Bancorp  Announces $0.06 Quarterly Dividend
First Internet Bancorp Announces $0.06 Quarterly Dividend
DAOstack One Day Trading Volume Hits $477.00
DAOstack One Day Trading Volume Hits $477.00
Wixlar  Trading 19.7% Higher  This Week
Wixlar Trading 19.7% Higher This Week
Commercial National Financial Corp  to Issue None Dividend of $1.00
Commercial National Financial Corp to Issue None Dividend of $1.00
COS Trading Down 1.1% Over Last Week
COS Trading Down 1.1% Over Last Week
TPG RE Finance Trust Inc  Plans $0.43 Quarterly Dividend
TPG RE Finance Trust Inc Plans $0.43 Quarterly Dividend


© 2006-2019 Ticker Report